At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01672 ASCLETIS-B
Trading 07-29 11:33:48
8.770
-0.170
-1.90%
High9.030Low8.710Vol1.36M
Open8.950D1 Closing8.940Amplitude3.58%
Mkt Cap9.23BTradable Cap9.23BTotal Shares1.05B
T/O11.93MT/O Rate0.13%Tradable Shares1.05B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Ascletis Pharma - Ind Applications for Asc37 Sq and Oral Formulations to be Submitted in Q3 2026
THOMSON REUTERS  ·  07-27 18:10
Ascletis Pharma - Ind Applications for Asc37 Sq and Oral Formulations to be Submitted in Q3 2026
Ascletis Announces Once-Monthly Subcutaneously Administered Glp-1R/Gipr/Gcgr Triple Peptide Agonist, Asc37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
THOMSON REUTERS  ·  07-27 18:10
Ascletis Announces Once-Monthly Subcutaneously Administered Glp-1R/Gipr/Gcgr Triple Peptide Agonist, Asc37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model
Ascletis Pharma - Announces Asc37 Demonstrates Superior Weight Loss in Obese Mouse Model
THOMSON REUTERS  ·  07-27 18:06
Ascletis Pharma - Announces Asc37 Demonstrates Superior Weight Loss in Obese Mouse Model
Ascletis’ ASC37 Triple Agonist Delivers 88% Greater Weight Loss Than Tirzepatide; Monthly Injection and Oral BLA Filings Planned for 2026
Bulletin Express  ·  07-27 18:03
Ascletis’ ASC37 Triple Agonist Delivers 88% Greater Weight Loss Than Tirzepatide; Monthly Injection and Oral BLA Filings Planned for 2026
Ascletis Says ASC37 Triple Agonist Posts 88% Greater Weight Loss than Tirzepatide in Obese Mice
Reuters  ·  07-27 18:02
Ascletis Says ASC37 Triple Agonist Posts 88% Greater Weight Loss than Tirzepatide in Obese Mice
Ascletis Pharma Files HKEX Next-day Return Disclosing Share Repurchase for Cancellation
Reuters  ·  07-27 17:07
Ascletis Pharma Files HKEX Next-day Return Disclosing Share Repurchase for Cancellation
Ascletis Files HKEX Next-day Disclosure Return Reporting Share Repurchase for Cancellation
Reuters  ·  07-24
Ascletis Files HKEX Next-day Disclosure Return Reporting Share Repurchase for Cancellation
Ascletis Announces Oral Discussion of Asc36_35 Fdc Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/tirzepatide Combination at the 62nd European Association for the Study of Diabetes (easd) Annual Meeting
THOMSON REUTERS  ·  07-23
Ascletis Announces Oral Discussion of Asc36_35 Fdc Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/tirzepatide Combination at the 62nd European Association for the Study of Diabetes (easd) Annual Meeting
Ascletis Pharma Files HKEX Next-day Disclosure Return Reporting Share Repurchase for Cancellation
Reuters  ·  07-20
Ascletis Pharma Files HKEX Next-day Disclosure Return Reporting Share Repurchase for Cancellation
ASCLETIS Executes Share Buyback, Spending HK$2.58 Million on July 17
Stock News  ·  07-17
ASCLETIS Executes Share Buyback, Spending HK$2.58 Million on July 17
Ascletis Pharma Files HKEX Next-day Return Disclosing Share Repurchase for Cancellation
Reuters  ·  07-17
Ascletis Pharma Files HKEX Next-day Return Disclosing Share Repurchase for Cancellation
Ascletis Advances First-in-Class Oral GLP-1R/GIPR Combo; IND Filing Planned for Q4 2026
Bulletin Express  ·  07-15
Ascletis Advances First-in-Class Oral GLP-1R/GIPR Combo; IND Filing Planned for Q4 2026
Ascletis Selects Oral Glp-1/gip Fixed-dose Combo Asc30_48 for Clinical Development in Obesity
Reuters  ·  07-15
Ascletis Selects Oral Glp-1/gip Fixed-dose Combo Asc30_48 for Clinical Development in Obesity
Ascletis Pharma - Ind Submission to FDA for Asc30_48 Fdc Oral Tablets Expected in Q4 2026
THOMSON REUTERS  ·  07-15
Ascletis Pharma - Ind Submission to FDA for Asc30_48 Fdc Oral Tablets Expected in Q4 2026
Ascletis Pharma - Asc30_48 Fdc Shows 52% Greater Body Weight Reduction vs Asc30 Monotherapy in Nhp Study
THOMSON REUTERS  ·  07-15
Ascletis Pharma - Asc30_48 Fdc Shows 52% Greater Body Weight Reduction vs Asc30 Monotherapy in Nhp Study
ASCLETIS-B Chooses Fixed-Dose Combination of Pioneering Oral Small Molecule GIPR Agonist ASC48 and Oral GLP-1R Agonist ASC30 for Clinical Development
Stock News  ·  07-15
ASCLETIS-B Chooses Fixed-Dose Combination of Pioneering Oral Small Molecule GIPR Agonist ASC48 and Oral GLP-1R Agonist ASC30 for Clinical Development
Ascletis Pharma - Selects Fixed-dose Combination of Asc48 and Asc30 for Clinical Development
THOMSON REUTERS  ·  07-15
Ascletis Pharma - Selects Fixed-dose Combination of Asc48 and Asc30 for Clinical Development
Ascletis Accelerates Buyback: Acquires 0.20 Million Shares for HK$2.09 Million, Lifts 2026 Repurchase Total to 0.55 Million
Bulletin Express  ·  07-14
Ascletis Accelerates Buyback: Acquires 0.20 Million Shares for HK$2.09 Million, Lifts 2026 Repurchase Total to 0.55 Million
ASCLETIS-B (01672) Allocates HK$2.09 Million for Share Buyback on July 14
Stock News  ·  07-14
ASCLETIS-B (01672) Allocates HK$2.09 Million for Share Buyback on July 14
Ascletis Pharma Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation
Reuters  ·  07-14
Ascletis Pharma Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation

Introduction

Company Name.
ASCLETIS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The Company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others. The Company conducts its business in the domestic and overseas markets.
Issue price:
--